Lataa...
IL-15 in the Combination Immunotherapy of Cancer
We completed clinical trials of rhIL-15 by bolus, subcutaneous, and continuous intravenous infusions (CIV). IL-15 administered by CIV at 2 mcg/kg/day yielded a 38-fold increase in 10- day number of circulating NK cells, a 358-fold increase in CD56(bright) NK cells and a 5.8-fold increase in CD8 T ce...
Tallennettuna:
| Julkaisussa: | Front Immunol |
|---|---|
| Päätekijät: | , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Frontiers Media S.A.
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7248178/ https://ncbi.nlm.nih.gov/pubmed/32508818 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2020.00868 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|